Go Back Menu
Close
Download Annual Report
FY 2023-24
Mankind Pharma Ltd
NSE: MANKIND
-
OUR PERFORMANCE IN FY 2023-24
Spearheading our growth trajectory
for a healthy Bharat
for a healthy Bharat
₹10,335 Cr
Revenue from Operations
Up 18% from last year
24.7%
EBITDA Margins
Up 280 bps from last year
₹1,942 Cr
Net Profit
Up 48% from last year
₹47.74
Earnings Per Share
Up 49% from last year
Mankind Pharma
at a glance
at a glance
Mankind Pharma is one of the fastest-growing companies in the Indian Pharmaceutical Market (IPM), driven by quality and affordability. Our robust portfolio has led to volume-led growth, outpacing IPM growth. We focus on R&D, innovation, and delivering integrated solutions to our valued customers.
The data presented below pertains exclusively to Mankind Pharma and does not include contributions from BSV.
The data presented below pertains exclusively to Mankind Pharma and does not include contributions from BSV.
Strong Presence and Coverage
Volume-led Growth
Commitment to Quality
Execution Excellence
16,000+
Field Force
13,000+
Stockists
5,00,000+
Doctors
#1
Rank in
Prescriptions
Prescriptions
#2
Rank in Covered
Market Volume
Market Volume
#3
Rank by
Volume
Volume
#4
Rank by
Value
Value
150+ Crore
Medicine strips sold
in FY24
in FY24
~200 SKUs
Launched in India having DMF grade APIs
~75%
In-house Manufacturing
1.3x Outperformance
Consistently in the IPM
Scaled up 23 Brands
Over ₹100 Cr. in less than three decades
Creating long-term value
for our investors
for our investors
Tools for quick analysis
view
price chart
Calculate
historic returns
The chart above is showing Mankind Pharma BSE stock price. Last updated price as per previous market closing price
What if you had invested
in Mankind
in Mankind
before a period of
You would have
₹23,580
(135.80%)
Get in touch with our
Investor Relations team
Investor Relations team
What's new with Mankind?
